Stefan Timmerman

Stefan Timmerman

Auto-generated profile, based on publicly available information

Stefan Timmerman

Department of Development and Regeneration KU Leuven Leuven Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
STStefan Timmerman
Stefan Timmerman
LSLauren Stubbe
Lauren Stubbe
TBThierry Van Den Bosch
Thierry Van Den Bosch
DSDominique Van Schoubroeck
Dominique Van Schoubroeck
TTTina Tellum
Tina Tellum
WFWouter Froyman
Wouter Froyman
Introduction: Accessory cavitated uterine malformation (ACUM) is a relatively recent term used to describe a noncommunicating, accessory uterine cavity. ACUM have been published under different terms ranging from juvenile cystic adenomyosis to “uterus‐like mass”. The objective of this study was to systematically identify all cases of ACUM and definitions described in the literature, regardless of label, and identify morphological, epidemiological, and clinical characteristics as well as management, while also highlighting knowledge gaps.Material and methods: A systematic literature search of three databases was performed, reviewing all records of cystic myometrial lesions. Cases that fitted common definitions for ACUM were included and clinical and imaging characteristics were documented in detail. This work was registered to PROSPERO and reporting followed PRISMA guidelines for scoping reviews.Results: A total of 53 articles were included, comprising 115 cases that met the minimal criteria for ACUM. The median age at onset of symptoms was 17 years, presenting with dysmenorrhea soon after menarche. A total of 19 women were parous. On ultrasound, ACUM appears as unilocular myometrial cysts, usually with ground‐glass content. Hemorrhagic content is also observed on magnetic resonance imaging (MRI), with high signal intensity on both T2 and T1‐weighted images. Ninety‐five (83%) cases were managed surgically, with a trend towards primary nonsurgical options. Although no adverse outcomes were reported, long‐term follow‐up on subsequent fertility and pregnancy was rare.Conclusions: Despite its increasing recognition as a clinical entity, ACUM often remains underdiagnosed as it shares similarities with other myometrial masses. We propose a unified terminology and definition for ACUM based on the data in this review. ACUM presents as a cavitated lesion, surrounded by a myometrial mantle, in continuity with the anterolateral uterine wall and located beneath the insertion of the round ligament and the interstitial portion of the fallopian tube. In contrast to other uterine abnormalities, a normal uterine cavity is visualized. Future studies are needed, using a clear definition for ACUM, and prospectively investigating management strategies, including long‐term follow‐up of patient‐reported symptoms, fertility, and pregnancy outcomes.

15 September 2022 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
RHR. Heremans
R. Heremans
LVLil Valentin
Lil Valentin
PSP. Sladkevicius
P. Sladkevicius
STS. Timmerman
S. Timmerman
FMFrancesca Moro
Francesca Moro
WFWouter Froyman
Wouter Froyman

5 April 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
CBChristine De Bruyn
Christine De Bruyn
JCJ. Ceusters
J. Ceusters
KBK. Vanden Brande
K. Vanden Brande
STS. Timmerman
S. Timmerman
WFWouter Froyman
Wouter Froyman
TBT. Van Den Bosch
T. Van Den Bosch

16 August 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
MPM.Angela Pascual
M.Angela Pascual
LVL. Vancraeynest
L. Vancraeynest
STS. Timmerman
S. Timmerman
JCJ. Ceusters
J. Ceusters
ALA. Ledger
A. Ledger
WFWouter Froyman
Wouter Froyman

21 March 2025 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
DFDaniela Fischerova
Daniela Fischerova
FPF. Planchamp
F. Planchamp
JAJ. L. Alcázar
J. L. Alcázar
PDP. Dundr
P. Dundr
EEE. Epstein
E. Epstein
USU. Scovazzi
U. Scovazzi
The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) with the European Society of Gynaecological Oncology (ESGO) jointly developed clinically relevant and evidence‐based statements on performing ultrasound‐guided biopsies in gynecological oncology.The objective of this Consensus Statement is to assist clinicians, including gynecological sonographers, gynecological oncologists and radiologists, to achieve the best standards of practice in ultrasound‐guided biopsy procedures. ISUOG/ESGO nominated a multidisciplinary international group of 16 experts who have demonstrated leadership in the use of ultrasound‐guided biopsy in the clinical management of patients with gynecological cancer. In addition, two early‐career gynecological fellows were nominated to participate from the European Network of Young Gynae Oncologists (ENYGO) within ESGO and from ISUOG. The group also included a patient representative from the European Network of Gynaecological Cancer Advocacy Groups. The document is divided into six sections: (1) general recommendations; (2) image‐guided biopsy (imaging guidance, sampling methods); (3) indications and contraindications; (4) technique; (5) reporting; and (6) training and quality assurance. To ensure that the statements are evidence‐based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on this review of the literature. During a conference call, the whole group discussed each preliminary statement, and a first round of voting was carried out. The group achieved consensus on all 46 preliminary statements without the need for revision.These ISUOG/ESGO statements on ultrasound‐guided biopsy in gynecological oncology, together with a summary of the evidence supporting each statement, are presented herein. This Consensus Statement is supplemented by detailed narrated videoclips presenting different approaches and indications for ultrasound‐guided biopsy, a patient leaflet, and an extended version which includes a detailed review of the evidence. © 2025 The Authors. Published by John Wiley & Sons Ltd on behalf of The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) and by Elsevier Inc. on behalf of the European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.

13 March 2025 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
EPEllen De Pauw
Ellen De Pauw
BGBeau Gommers
Beau Gommers
Marjolein M. EnsinckMarjolein M. Ensinck
Marjolein M. Ensinck
STStefan Timmerman
Stefan Timmerman
SVSilke De Vriendt
Silke De Vriendt
HVHugo Vankelecom
Hugo Vankelecom
Cystic fibrosis (CF) is a life-shortening genetic disorder, caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that regulates ion and fluid transport in epithelial tissue. Female CF patients face considerable fertility challenges, with higher prevalence of deficient fertility compared to healthy women. Not much is known about the underlying causes. In particular, the pathobiology of the endometrium, the uterus' inner lining essential for pregnancy and expressing fluctuating CFTR levels during the menstrual cycle, is unexplored in CF. To address this gap, we developed organoid models from CF patient endometrium. The organoids recapitulated CF characteristics and revealed molecular and pathway differences in cycle-recapitulating hormone responses compared to healthy endometrial organoids. Furthermore, specific functional aberrations were restored by CFTR modulator treatment. To further complement human organoid models for unraveling endometrial pathobiology in CF, we also developed organoids from a genetic CF mouse model that were also found to recapitulate CF characteristics. Moreover, single-cell RNA-sequencing analysis of the CF mouse uterus revealed molecular traits in the endometrium similar to the human CF endometrium (as evidenced by its organoid model). Our study provides new endometrium models to advance our understanding of CF-associated endometrial pathobiology, particularly regarding menstrual cycle aberrations that impact fertility. This research is timely since improved CF therapeutics result in increased life expectancy, allowing more CF patients to consider starting a family.